Introduction to Antagonistic Antibody Discovery by Phage Display

Therapeutic antibodies constitute a novel category of biological drugs that have gained prominence in recent years. Their impact on disease treatment is becoming increasingly evident. Among these, antagonist antibody drugs are particularly significant. Antagonist antibodies belong to a class that binds to receptors, preventing agonists from exerting their effects. Currently, these antagonist antibodies have significant therapeutic applications in the treatment of cancer, hemophilia, autoimmune disorders, transplant rejection, and metabolic diseases. Based on our rich field experience and advanced phage display platform, Creative Biolabs provides comprehensive services for custom antagonistic antibodies and checkpoint antagonistic antibodies to support antagonistic antibody therapy development.

Antibody (Creative Biolabs Authorized)

Antagonistic Antibody Therapy

Antagonist antibodies are antibodies with antagonistic activity. They have chemical affinity for the corresponding receptor but lack potency, hindering the agonist's impact. These antibodies can bind to the receptor's active site, an allosteric site, or even a site without bioregulatory effects.

Antagonist antibody therapies hold great promise in cancer treatment. For instance, CXCR4 antagonists represent a promising avenue for cancer drug development. Normally, CXCR4 plays a key role in regulating cell migration and localization during development, homeostasis, and inflammation, aiding immune system activation and cell movement. However, dysregulation in the signaling pathway activating the receptor can lead to cancer cell growth, invasion, angiogenesis, and metastasis. Moreover, high expression of CXCR4 is also associated with poor prognosis and chemoresistance in many cancer subtypes, in part by enhancing the interaction between the cancer and the stroma. Clinical trials have shown that a human lgG4-type CXCR4 monoclonal antibody is a better solution for overcoming the slower time to remission and lower remission rates of BTK inhibitors in WM with CXCR4 mutations, and this mAb is currently in development for phase 2 clinics in the Wahl's macroglobulinemia indication. In addition, elevated adenosine levels and A2AR activation become important pathways for tumor immune escape. They can affect the immune process from different perspectives. For example, adenosine/A2AR activation can activate the downstream adenylate cyclase and thus upregulate cyclic adenosine monophosphate levels, and cAMP can affect the immune cells and immune process through protein kinase A. Therefore, blockade of the adenosine/A2AR pathway has also become an important direction in tumor immunotherapy. Checkpoint antagonist antibodies, such as CTLAA antibodies, play a significant role in cancer treatment by transmitting inhibitory signals and acting as immune checkpoints to down-regulate or terminate T-cell activation. CTLA4 antagonist antibodies are mainly used in the treatment of melanoma, renal carcinoma, and lung cancer.

There are also many autoimmune diseases that can be treated with antagonist antibodies, such as dry syndrome. Studies have shown that by developing antagonists targeting IL-1, TNF-α, CD40, IL-6, and other targets, the over-activation of the targets is disturbed, which in turn effectively relieves the different symptoms of dry syndrome.

More Details on Antagonistic Antibody Discovery by Phage Display

Introduction to Checkpoint Antagonistic Antibody Discovery by Phage Display
Introduction to Antagonistic Autoantibody Discovery by Phage Display

Creative Biolabs has a wealth of knowledge and experience in custom antagonistic antibodies. We would be happy to share our knowledge and experience in antagonistic antibody discovery by phage display with you.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: